Clinical Trial Update: Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Congenital Hemophilia A [Phase 3]

View source ↗

Summary

Phase 3 trial update for modified recombinant Factor VIII (OBI-1) in congenital Hemophilia A; study terminated with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• OBI-1 (modified recombinant Factor VIII) (modified recombinant Factor VIII)

Snippet

Sponsor: Baxalta now part of Shire | Conditions: Hemophilia A | Phase 3 | Status: TERMINATED | Results posted: 2014-12-17